Suchergebnisse - "Liu, Xiaoqing"

PubPharm (14)

1

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study

enthalten in: Cancer communications (London, England) | 2024

von Zheng, J. | Wang, T. | Yang, Y. | +41

2

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations : A Phase 1 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Duan, J. | Wu, L. | Yang, K. | +32

3

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib : Results of Phase 3 ALTA-3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Yang, J. | Liu, G. | Lu, S. | +11

4

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC

enthalten in: Thoracic cancer | 2023

von Ma, X. | Zhang, K. | Xu, J. | +6

5

Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases : Open-Label Multicentre Dose-Expansion Phase Ib Study

enthalten in: Clinical lung cancer | 2022

von Zhou, Q. | Wang, M. | Zhang, H. | +5

6

Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer

enthalten in: Thoracic cancer | 2022

von Ma, X. | Yang, S. | Zhang, K. | +6

7

Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC : Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Lu, S. | Zhou, Q. | Liu, X. | +23

8

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC : Final Analysis, with a Focus on Patients Enrolled at Sites in China

enthalten in: Targeted oncology | 2022

von Tu, H. | Feng, J. | Shi, M. | +26

9

Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC : A Single-Arm, Multicenter Phase 2 Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2021

von Ai, X. | Wang, Q. | Cheng, Y. | +21

10

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC : a multicenter phase-II trial

enthalten in: Signal transduction and targeted therapy | 2021

von Jiang, T. | Wang, P. | Zhang, J. | +22